Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 8/20 | 1.00 |
| ▸ | HTR2A | P28223 | 7/20 | 1.00 |
| ▸ | DRD2 | P14416 | 7/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | HTR2C | P28335 | 5/20 | 1.00 |
| ▸ | HTR2B | P41595 | 5/20 | 1.00 |
| ▸ | DRD4 | P21917 | 4/20 | 1.00 |
| ▸ | HTR1D | P28221 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mianserin SCHEMBL9122085 | 1.00 | DRD3 (1.00) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL18020 | 1.00 | DRD3 (1.00) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL23326358 | 1.00 | DRD3 (1.00) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL353397 | 1.00 | DRD3 (1.00) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL340474 | 0.98 | MEN1 (1.00) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL11336834 | 0.98 | HTR2A (0.97) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL8344416 | 0.98 | DRD3 (0.97) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL29366576 | 0.98 | MEN1 (1.00) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL9752060 | 0.98 | DRD3 (0.97) | DRD3HTR2ADRD2HTR1AHTR2C | |
| Mianserin SCHEMBL9651849 | 0.97 | HTR2A (0.94) | DRD3HTR2ADRD2HTR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725483-A1 | COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE | Université de Bordeaux (FR) | 2026-04-15 | — | — | EP | claimed |
| WO-2022162265-A1 | ANTIMICROBIALS AGAINST PATHOGENS OF THE GENUS STREPTOCOCCUS | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2022-08-04 | — | — | WO | claimed |
| US-20260130884-A1 | PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERS | TRANSCEND THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4725483-A1 | COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE | Université de Bordeaux (FR) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724433-A2 | PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERS | Transcend Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260083699-A1 | PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERS | TRANSCEND THERAPEUTICS, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4678237-A2 | 5-HT7 ANTAGONIST FOR THE TREATMENT OF DEMENTIA-ASSOCIATED TAUOPATHIES | Medizinische Hochschule Hannover (MHH) (DE) | 2026-01-14 | — | — | EP | disclosed |
| US-12521426-B2 | Methods and compositions for inhibiting glyoxalase 1 (GLO1) | PALMER ABRAHAM (US) | 2026-01-13 | — | — | US | disclosed |
| WO-2025233488-A1 | LACTOBACILLUS SALIVARIUS STRAIN AND USES THEREOF | CHEMO RESEARCH, S.L. (ES) | 2025-11-13 | — | — | WO | disclosed |
| US-20250332139-A1 | PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERS | TRANSCEND THERAPEUTICS, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| EP-3856156-B1 | 5-HT7 ANTAGONIST FOR THE TREATMENT OF DEMENTIA-ASSOCIATED TAUOPATHIES | MEDIZINISCHE HOCHSCHULE HANNOVER MHH (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| CN-107592790-B | Pesticidal mixtures comprising carboxamide compounds and biopesticides | 巴斯夫农业化学品有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20220062194-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORP (US) | 2022-03-03 | — | — | US | disclosed |
| CN-114107426-A | Method for screening glutamine transport protein inhibitor, inhibitor screened by method and application of inhibitor | 苏州大学 | 2022-03-01 | — | — | CN | disclosed |
| US-20220053760-A1 | PEST CONTROL USING NATURAL PEST CONTROL AGENT BLENDS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2022-02-24 | — | — | US | disclosed |
| US-11241420-B2 | Compositions and methods for prophylaxis and treatment of addictions | OMEROS CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-20220031687-A1 | SYNERGIC PHARMACEUTICAL COMBINATION OF A LEUKOTRIENE-RECEPTOR ANTAGONIST AND AN INVERSE AGONIST OF HISTAMINE HI | Amezcua Amezcua, Federico (MX) | 2022-02-03 | — | — | US | disclosed |
| CN-113993522-A | Method for treating anxiety disorders, headache disorders and eating disorders with siloxibin | 指南针探路者有限公司 | 2022-01-28 | — | — | CN | disclosed |
| US-20220023257-A1 | TREATMENT OF DEMENTIA-ASSOCIATED TAUOPATHIES | DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E.V. (DZNE) (DE) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | DRD3 3138/4885HTR2A 3482/4885DRD2 3481/4885 |
| US-20220031687-A1 | SYNERGIC PHARMACEUTICAL COMBINATION OF A LEUKOTRIENE-RECEPTOR ANTAGONIST AND AN INVERSE AGONIST OF HISTAMINE HI | HRH4, HRH2, HRH1 | DRD3 1224/4885HTR2A 185/4885DRD2 1052/4885 |
| US-20220062194-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | DRD3 33/4885HTR2A 367/4885DRD2 25/4885 |
| US-20220023257-A1 | TREATMENT OF DEMENTIA-ASSOCIATED TAUOPATHIES | HTR7, MAPT, HTR1A | DRD3 319/4885HTR2A 10/4885DRD2 213/4885 |
| US-20260083699-A1 | PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERS | HTR2B, HTR1B, HTR5A | DRD3 15/4885HTR2A 6/4885DRD2 12/4885 |
| US-11241420-B2 | Compositions and methods for prophylaxis and treatment of addictions | OPRK1, OPRL1, PPARA | DRD3 93/4885HTR2A 177/4885DRD2 77/4885 |
| US-20260130884-A1 | PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERS | CYP2C19, HTR2B, HTR3B | DRD3 17/4885HTR2A 27/4885DRD2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.